Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia

N/ANot Yet RecruitingNCT06348095

Wecare Probiotics Co., Ltd.72 enrolled

Overview

To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Mycoplasma Pneumoniae Pneumonia

Interventions

ProbioticDIETARY_SUPPLEMENT

The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).

PlaceboDIETARY_SUPPLEMENT

The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 3 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Meet the diagnostic criteria for pneumonia in "Zhufutang Practical Pediatrics" (7th Edition), and is diagnosed with Mycoplasma pneumoniae pneumonia using tNGS technology; 2. Infants and young children aged 6 months to 3 years; 3. The course of the disease is \<48 h; 4. The family members of the children are informed about the study and sign the informed consent form. Exclusion Criteria: 1. Previous history of wheezing; 2. Cardiovascular disease and congenital tracheal dysplasia; 3. pneumonia induced by other causes; 4. Dysplasia of bronchial and pulmonary tracts; 5. premature infants; 6. Combined with immunosuppressive diseases; 7. Presence of mental illness.

Outcomes

Primary Outcomes

Mycoplasma pneumoniae load

Mycoplasma pneumoniae load was detected by tNGS

Time frame: 7天

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.